• Revenue and margin: The company expects at least 15% revenue growth this financial year and remains confident of sustaining EBITDA margins between 26% and 27% across its product mix.
• Capacity expansions: ATBS capacity has expanded from 30,000 to 50,000 tonnes with demand recovery expected from October, while Viral Organics is targeted to complete re-engineering by December to generate roughly ₹150 crore in initial revenue.
• Anisole sourcing: Management will treat Anisole as a make-or-buy decision depending on relative phenol and import prices to supply downstream production of MEHQ and other derivatives.
• ROCE trajectory: With the bulk of major capex already completed, ROCE is projected to stay at 15% to 16% in the near term before rising to around 20% over the next two to three years as asset utilization improves.